Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000947871-25-000926
Filing Date
2025-10-27
Accepted
2025-10-27 17:12:13
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 17337
2 JOINT FILING AGREEMENT ss5517697_ex9901.htm EX-99.1 5553
  Complete submission text file 0000947871-25-000926.txt   24598
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Filed by) CIK: 0001055951 (see all company filings)

EIN.: 133976876 | State of Incorp.: DE
Type: SCHEDULE 13D/A

Mailing Address 400 ALEXANDER PARK DRIVE SUITE 301 PRINCETON NJ 08540
Business Address 400 ALEXANDER PARK DRIVE SUITE 301 PRINCETON NJ 08540 (609) 642-6670
PMV Pharmaceuticals, Inc. (Subject) CIK: 0001699382 (see all company filings)

EIN.: 463218129 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-91714 | Film No.: 251420613
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)